Suchen
OPKO Health Inc
OPKZur Watchlist hinzufügen
1.100USD
0.0000.00%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
830.60MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über OPKO Health Inc Unternehmen
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
OPKO Health Inc Informationen
BörsenkürzelOPK
Name des UnternehmensOPKO Health Inc
IPO-datumNov 02, 1995
CEOCruz (Tony F)
Anzahl der mitarbeiter2997
WertpapierartOrdinary Share
GeschäftsjahresendeNov 02
Addresse- -
Stadt- -
BörseNASDAQ OMX - NASDAQ BASIC
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelOPK
IPO-datumNov 02, 1995
CEOCruz (Tony F)
Führungskräfte von OPKO Health Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
--
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
--
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
--
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Charles W. Bishop, Ph.D.
Dr. Charles W. Bishop, Ph.D.
Chief Executive Officer of OPKO Renal
Chief Executive Officer of OPKO Renal
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Ms. Yvonne K. Briggs
Ms. Yvonne K. Briggs
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
--
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
--
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
--
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Health Insurers
213.60M
57.69%
Client Payers
87.61M
23.66%
Government Payers
59.92M
16.18%
Patients
9.14M
2.47%
Nach RegionUSD
Name
Umsatz
Anteil
United States
436.06M
71.85%
Chile
62.38M
16.85%
Ireland
51.40M
13.88%
Spain
26.73M
7.22%
Mexico
25.52M
6.89%
Andere
-231.81M
-16.69%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Health Insurers
213.60M
57.69%
Client Payers
87.61M
23.66%
Government Payers
59.92M
16.18%
Patients
9.14M
2.47%
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.33%
Holbrook (Bruce C)
5.35%
Hsiao (Jane H)
4.39%
Frost Group, L.L.C.
4.31%
Andere
50.93%
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.33%
Holbrook (Bruce C)
5.35%
Hsiao (Jane H)
4.39%
Frost Group, L.L.C.
4.31%
Andere
50.93%
Aktionärstypen
Aktionäre
Anteil
Corporation
38.33%
Investment Advisor
12.75%
Individual Investor
11.15%
Hedge Fund
7.72%
Investment Advisor/Hedge Fund
5.59%
Research Firm
0.64%
Bank and Trust
0.24%
Pension Fund
0.13%
Venture Capital
0.05%
Andere
23.40%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
451
236.82M
31.36%
-9.38M
2025Q4
453
195.81M
25.51%
-55.48M
2025Q3
457
208.31M
27.13%
-63.18M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Frost Gamma Investments Trust
222.46M
29.31%
+2.15M
+0.98%
Nov 21, 2025
Rubric Capital Management LP
47.79M
6.3%
--
--
Dec 31, 2025
Holbrook (Bruce C)
40.38M
5.32%
--
--
Feb 24, 2025
Hsiao (Jane H)
33.13M
4.36%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.97%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
31.23M
4.11%
+1.54M
+5.20%
Dec 31, 2025
GJN 2021 Trust
19.91M
2.62%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.62%
--
--
Feb 24, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.53%
State Street SPDR S&P Health Care Services ETF
0.46%
VanEck Israel ETF
0.14%
Humankind US Stock ETF
0.1%
iShares U.S. Healthcare Providers ETF
0.1%
Goldman Sachs Innovate Equity ETF
0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.53%
State Street SPDR S&P Health Care Services ETF
Anteil0.46%
VanEck Israel ETF
Anteil0.14%
Humankind US Stock ETF
Anteil0.1%
iShares U.S. Healthcare Providers ETF
Anteil0.1%
Goldman Sachs Innovate Equity ETF
Anteil0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.05%
iShares Russell 2000 Value ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.04%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
